Clinical commissioning policy: Combination brentuximab vedotin and bendamustine for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma

Document first published:
Page updated:
Topic:
Publication type:

Brentuximab vedotin and bendamustine is recommended to be available as a routine commissioning treatment option for patients aged 8 years and above in relapsed and refractory classical Hodgkin lymphoma within the criteria set out in this document.

Document

Clinical commissioning policy: Combination brentuximab vedotin and bendamustine (BVB) for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma

Clinical commissioning policy: Combination brentuximab vedotin and bendamustine (BVB) for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma

  • PDF
  • 286 KB
  • 8 pages

Summary

Published 16 July 2026.